Phase 2 PROSPECT Study Presented by Lakshmi Nayak, MD.

Lakshmi Nayak, MD presented results from a phase 2 PROSPECT study focused on  tirabrutinib and it's effect on patients with relapsed or refractory primary central nervous system lymphoma.